BRCA Testing

For women with ovarian cancer, early identification of BRCA mutations can help determine the most appropriate treatment plan, and if the mutation is germline, can also support identification of family members at risk, and reduce future cancers through potential interventions.1–3

Whilst germline BRCA testing for women with ovarian cancer is now commissioned by NHS England, funding for tumour BRCA testing remains limited.4,5 Therefore, to support identification of these women, AstraZeneca is providing a tumour BRCA testing service  at certain sites in the UK for patients who meet the eligibility criteria.

Here you can find out more about BRCA testing, what the AstraZeneca tumour BRCA testing service is and how you can access it.

Tumour BRCA testing service

AstraZeneca are offering a tumor BRCA testing service at specified collaboration laboratories for patients who meet the eligibility criteria. This is to ensure patients who have a somatic BRCAm are identified and are given the opportunity to access treatments such as Lynparza capsules.

Who is eligible for this service?

Patients who are eligible for this service are those that have ovarian cancer and either a known negative germline BRCA mutation status or an unknown germline BRCA mutation status. Patients must have received at least two prior lines of treatment (i.e. patient is third line or beyond).

Who is eligible for this service?
Who is eligible for this service?